verapamil has been researched along with Epilepsies, Partial in 3 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Epilepsies, Partial: Conditions characterized by recurrent paroxysmal neuronal discharges which arise from a focal region of the brain. Partial seizures are divided into simple and complex, depending on whether consciousness is unaltered (simple partial seizure) or disturbed (complex partial seizure). Both types may feature a wide variety of motor, sensory, and autonomic symptoms. Partial seizures may be classified by associated clinical features or anatomic location of the seizure focus. A secondary generalized seizure refers to a partial seizure that spreads to involve the brain diffusely. (From Adams et al., Principles of Neurology, 6th ed, pp317)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Two patients with mild symptoms were rechallenged with a lower verapamil dosage (120 mg twice a day) and showed similar rises in CBZ concentration and recurrent neurotoxic symptoms." | 2.66 | Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction. ( Brodie, MJ; Macphee, GJ; McInnes, GT; Thompson, GG, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Langer, O | 1 |
| Bauer, M | 1 |
| Hammers, A | 1 |
| Karch, R | 1 |
| Pataraia, E | 1 |
| Koepp, MJ | 1 |
| Abrahim, A | 1 |
| Luurtsema, G | 1 |
| Brunner, M | 1 |
| Sunder-Plassmann, R | 1 |
| Zimprich, F | 1 |
| Joukhadar, C | 1 |
| Gentzsch, S | 1 |
| Dudczak, R | 1 |
| Kletter, K | 1 |
| Müller, M | 1 |
| Baumgartner, C | 1 |
| Macphee, GJ | 1 |
| McInnes, GT | 1 |
| Thompson, GG | 1 |
| Brodie, MJ | 1 |
| Karpova, MN | 1 |
| Glebov, RN | 1 |
| Kryzhanovskiĭ, GN | 1 |
| Agatova, OL | 1 |
1 trial available for verapamil and Epilepsies, Partial
| Article | Year |
|---|---|
Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction.
Topics: Adult; Carbamazepine; Clinical Trials as Topic; Dizziness; Double-Blind Method; Drug Synergism; Drug | 1986 |
2 other studies available for verapamil and Epilepsies, Partial
| Article | Year |
|---|---|
Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil.
Topics: Adult; Age of Onset; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain; Carbon Radioiso | 2007 |
[Effect of verapamil on focal epileptic activity in the rat cerebral cortex].
Topics: Animals; Cerebral Cortex; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Electroenc | 1987 |